Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
As the first oral GLP-1 treatment for people living with overweight or obesity, the Wegovy pill provides patients with a new, convenient treatment option that can help patients start or continue their weight loss journey, Mike Doustdar, president and CEO of Novo Nordisk, said in a statement heralding the approval of the oral version of Wegovy
Additionally, it can act as an appetite suppressant, though this side effect is not typically the primary reason people seek it out
Presented for research literature review only Trappe SW et al
AACE = American Association of Clinical Endocrinology
60 Capsules
US$ 24.19
US$ 24.15
US$ 22.06
US$ 28.77
